Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
17 evidence topics · 15 sources
Summary: anticipated place in therapy
Palazestrant has no approved indication. The company plans to submit a new drug application in 2027 for monotherapy in second- and third-line ER+/HER2- metastatic breast cancer and anticipates commercial launch in 2028. The FDA Fast Track designation covers ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. In OPERA-01, participants whose disease advanced after at least one endocrine therapy given with a CDK4/6 inhibitor are enrolled “regardless of ESR1 mutation status” and, in Part 2, randomized 1:1 to palazestrant 90 mg once daily or investigator's choice of standard-of-care endocrine therapy (fulvestrant, letrozole, anastrozole, or exemestane). The company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. The approved oral agents in the same setting, elacestrant, imlunestrant, and vepdegestrant, are each indicated only for ESR1-mutated disease after at least one line of endocrine therapy, and the NCCN guideline lists elacestrant, imlunestrant, or vepdegestrant for ESR1-mutated tumors, aromatase inhibitor monotherapy as a subsequent-line option, and fulvestrant with alpelisib or capivasertib for PIK3CA, AKT1, or PTEN alterations. The ESMO 2026 guideline states that at least two lines of endocrine-based therapy can be recommended before non-endocrine therapy in endocrine-sensitive disease and that a fulvestrant–CDK4/6 inhibitor switch or, to a lesser extent, fulvestrant monotherapy may be considered in the absence of targetable alterations. The ABC8 consensus recommends switching the endocrine mechanism of action when resistance emerges, reports oral SERD hazard ratios of 0.55 to 0.62 in ESR1-mutated tumors, and states that “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials”. In one cohort treated after first-line CDK4/6 inhibitor therapy, second-line treatment was cytotoxic chemotherapy in 29.7% of 839 participants, endocrine monotherapy in 12.4%, and continued CDK4/6 inhibitor in 36.0%. Palazestrant is taken orally once daily, whereas fulvestrant is given as two intramuscular injections every 28 days, with injections “mainly requiring in-office administration”. The company plans a field force of approximately 75 to 100 representatives “to cover U.S. breast oncologists” and is studying palazestrant with ribociclib in the first line in OPERA-02, with the goal of positioning it as the “endocrine therapy of choice in the first-line setting”.
Proposed initial line of therapy: monotherapy in the second- and third-line setting
Company positioning for both ESR1-mutated and ESR1 wild-type tumors
Company estimates of United States incidence and market size in the second- and third-line setting
Planned commercial launch and prescriber audience
Company positioning as an endocrine backbone and first-line combination partner
Planned first-line use with ribociclib (OPERA-02)
Company description of endocrine sequencing in metastatic disease
ESMO guideline sequence for second-line and later endocrine-based therapy
ABC8 consensus on switching endocrine mechanism and oral SERD sequencing
“In general, when resistance emerges, switching the mechanism of action of endocrine therapy, with or without adding targeted treatment, is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine-based regimens preferred after a CDK4/6 inhibitor
Oral once-daily administration and the outpatient care setting
Intramuscular fulvestrant requires in-office administration
Company description of fulvestrant administration
Real-world second-line treatment after first-line CDK4/6 inhibitor in the United States
“Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively. Fulvestrant was the most commonly prescribed endocrine monotherapy (70 patients, 8.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three hundred two (36.0%) of patients continued a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world second- and third-line treatment after first-line CDK4/6 inhibitor in a European cohort
“In the second-line setting ( n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the third-line setting ( n = 95), treatment options were more heterogeneous, including endocrine monotherapy (2%; n = 2), targeted therapies (29%; n = 27), capecitabine (36%; n = 34), other chemotherapy (26%; n = 25), and ADCs (7%; n = 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote